Current stock page

Financial Data

ANAB Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ANABAnaptysBio, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$46.25−$1.52 (−3.18%)

Latest quote

  • Momentum
    36
  • Value
    74
  • Quality
    72
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$30.27M$27.49M$25.56M$108.25M$76.32M$22.26M$27.77M$43.11M
Gross Profit$19.91M$14.15M$24.95M$216.24M$44.91M-$15.56M-$13.41M$524K
Operating Income$19.91M$14.15M-$34.64M$66.9M$34.7M-$26.17M-$27.54M-$9.67M
Net Income$3.88M$183.88M-$52.88M$49.61M$15.11M-$38.63M-$39.33M-$21.78M
EPS$0.13$6.28-$1.84$1.79$0.52-$1.34-$1.28-$0.77
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$9.54M-$26.64M-$25.92M$98M-$27.36M-$40.24M-$10.7M-$66.67M
Capital Expenditure$0$17K-$17K-$1K-$12K-$39K-$35K-$263K
Free Cash Flow-$9.54M-$26.62M-$25.94M$98M-$27.37M-$40.28M-$10.74M-$66.94M
Net Cash Provided By Operating Activities-$9.54M-$26.64M-$25.92M$98M-$27.36M-$40.24M-$10.7M-$66.67M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$307.04M$316.98M$329.68M$364.4M$353.1M$335.25M$422.05M$483.83M
Total Debt$12.57M$269.59M$277.36M$290.64M$346.45M$15.1M$15.58M$16.04M
Cash And Cash Equivalents$135.39M$133.83M$248.47M$238.2M$109.83M$44.3M$98.64M$123.08M
Total Liabilities$286.22M$306.4M$316.94M$327.19M$382.51M$379.98M$388.03M$412.97M
Total Stockholders Equity$20.82M$10.59M$12.75M$37.21M-$29.42M-$44.73M$34.02M$70.87M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio8.7910.09——————
P/B ratio153.24186.66147.6144.5——18.677.05
P/S ratio8.47———————
Debt To Equity0.625.4721.767.81——0.460.23
Free Cash Flow Yield2.21%0.91%0.23%1.18%-14.42%-19.72%-17.18%-27.17%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio8.7910.09——————
P/B ratio153.24186.66147.6144.5——18.677.05
P/S ratio8.47———————
Return On Equity8.86%18.49%-210.14%-35.56%——-4.13%-204.93%
Debt To Equity0.625.4721.767.81——0.460.23

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe7.27x
Pb66.3x
Revenue Growth Yoy-60.33%
EPS Growth Yoy-75.00%
Gross Margin143.68%
Operating Margin34.62%
ROE906.99%
ROIC-1014.49%
Debt To Equity0.6
FCF Yield2.60%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$46.25
Volume499,638
RSI (14)42.73
MACD-0.59
MACD signal-0.69
MACD histogram0.1
ADX (14)23.7
SMA (50)$49.79
SMA (200)$56.50
ATR (14)$2.13
Historical volatility (annualized)51.79%
Volume (20-day average)409,593

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score46/100
Beta1.11
Annual volatility64.84%
Max Drawdown-35.30%
Sharpe Ratio0.78
VaR (95%, 1-day)-5.33%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ANAB Financial Data FAQ

What is AnaptysBio, Inc.'s revenue?

AnaptysBio, Inc.'s revenue is one of the core financial data points for ANAB. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is AnaptysBio, Inc.'s revenue growing?

Revenue growth shows whether AnaptysBio, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ANAB's EPS?

ANAB's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is AnaptysBio, Inc.'s net income?

AnaptysBio, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does AnaptysBio, Inc. generate?

Free cash flow shows how much cash AnaptysBio, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does AnaptysBio, Inc. have?

Cash and debt help frame ANAB's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.